Edgewise TherapeuticsEWTX
About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Employees: 117
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
88% more call options, than puts
Call options by funds: $61.6M | Put options by funds: $32.7M
11% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 61
11% more funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 10 (+1) [Q1 2025]
6.04% more ownership
Funds ownership: 104.54% [Q4 2024] → 110.57% (+6.04%) [Q1 2025]
5% less funds holding
Funds holding: 199 [Q4 2024] → 190 (-9) [Q1 2025]
12% less capital invested
Capital invested by funds: $2.64B [Q4 2024] → $2.32B (-$322M) [Q1 2025]
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis | 192%upside $42 | Buy Initiated | 30 Jun 2025 |
RBC Capital Leonid Timashev | 234%upside $48 | Outperform Reiterated | 5 Jun 2025 |
Financial journalist opinion
Based on 11 articles about EWTX published over the past 30 days
